source
- Lilly, Gilead lead pharma’s M&A boomDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.BioPharma Dive · 4mo ago↗ source
- STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and moreAn FDA proposal to remove references to “gender” from its regulations sparked concerns about unintended consequences on researchSTAT · 4mo ago↗ source
- The aging scientific workforce collides with rising fabricating citations in medical journalsThe latest in the hantavirus cruise ship saga, why these former officials left the FDA, and more health news from Morning RoundsSTAT · 4mo ago↗ source